Trinseo’s MAGNUM 8391 MED ABS Resins, are part of the company’s line of performance plastics tailored for medical device applications. Trinseo’s proprietary polymerization process results in a material that is highly consistent from lot-to-lot in terms of color, rheology and physical properties. The process results in brilliant whiteness of the material for ease of coloring and less pigment use, and results in lower residual monomers and oligomers.
Medical-industry requirements found in MAGNUM 8391 MED include biocompatibility, chemical resistance, sterilization options, and comprehensive regulatory support. The material also offers an extended notification of change as well as the versatility of secondary operations common in medical equipment, such as spraying, plating, solvent bonding, and ultrasonic welding.
To ensure the quality required for medical applications, Trinseo adheres to strict production guidelines. Its medical manufacturing facilities and related global departments are ISO 13485:2016 certified, which places a special emphasis on risk management and process validation.
Trinseo provides the medical device industry with materials for single- and multiple-use devices and equipment housings.
Trinseo is focused on delivering innovative and sustainable solutions to help its customers create products that touch lives every day across a wide range of end-markets, including automotive, consumer electronics, appliances, medical devices, lighting, electrical, carpet, paper and board, building and construction, and tires. Trinseo had approximately $3.7 billion in net sales in 2016, with 15 manufacturing sites around the world, and nearly 2,200 employees. The company is based in Berwyn, Pa.